Immune rejection

Immune rejection is a process in which the immune system of an organism identifies and attacks a foreign body, such as a transplanted organ, tissue, or cell, considering it as an invader or a threat. This phenomenon is a significant concern in the field of transplantation medicine, where the success of organ and tissue transplants depends on the ability to manage and prevent rejection. Immune rejection is categorized into several types, including hyperacute rejection, acute rejection, and chronic rejection, each differing in their time of onset and underlying immune mechanisms.

Types of Immune Rejection

Hyperacute Rejection

Hyperacute rejection occurs within minutes to hours after transplantation. It is mediated by pre-existing antibodies in the recipient that react against the graft. This type of rejection is now rare due to the pre-transplant screening for donor-recipient HLA compatibility and the presence of antibodies.

Acute Rejection

Acute rejection happens days to weeks after the transplant. It involves a cell-mediated immune response primarily driven by T cells against the transplanted tissue. Despite improvements in immunosuppressive therapies, acute rejection remains a challenge in transplantation.

Chronic Rejection

Chronic rejection can take place over months to years and is characterized by the gradual loss of graft function. This type involves both cellular and humoral immune responses, leading to fibrosis and organ failure. The exact mechanisms of chronic rejection are not fully understood and represent a significant area of research.

Mechanisms of Immune Rejection

The immune system employs several mechanisms to reject foreign tissues. These include the activation of T cells, which recognize foreign antigens presented by Major Histocompatibility Complex (MHC) molecules on the surface of donor cells. Antibodies produced by B cells can also play a role by binding to antigens on the graft and activating the complement system, leading to cell lysis or opsonization.

Prevention and Management

The prevention and management of immune rejection primarily involve the use of immunosuppressive drugs to dampen the immune response against the transplanted organ or tissue. These drugs include corticosteroids, calcineurin inhibitors (such as tacrolimus and cyclosporine), mTOR inhibitors, and antiproliferative agents. Despite their effectiveness, these medications can have significant side effects and increase the risk of infections and cancer due to the suppressed immune function.

Future Directions

Research in the field of transplantation is focused on developing more specific and less toxic immunosuppressive strategies, including the use of tolerance induction techniques that aim to train the recipient's immune system to accept the transplanted tissue without the need for lifelong immunosuppression. Additionally, advances in genetic engineering and stem cell therapy hold promise for creating grafts that are less prone to rejection.

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian